Efficacy of Targeted mRNA Therapeutics in Refractory Autoimmune Disorders: A Phase II Clinical Trial
DOI:
https://doi.org/10.70088/ba518d61Keywords:
mRNA therapeutics, autoimmune disorders, clinical trial, immune modulation, targeted therapyAbstract
This research article enquire the efficaciousness of remedy in treating refractory autoimmune disorders through a Phase II clinical tryout. Autoimmune disorders frequently reject discussion, require innovational approaches. Targeted mRNA remedy offer a bright boulevard by tone immune responses at the molecular grade. To value clinical effect, safety profiles, and and immunologic mark in patient with conditions, the subject employed a randomized, -unsighted methodology. Outcome demonstrated significant betterment in disease activity scores, repress seditious marker, and raise patient-cover outcomes compared to placebo. The determination underline the potential of mRNA-based treatment as a strategy for autoimmune disease. On optimize delivery mechanisms and search liberal applications. Inquiry should focus.References
J. F. Howard, "Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis," Mol. Ther., 2026.
Q. Li, M. Zeng, W. Lv, J. Ye, and S. Wu, "Current landscape of clinical trials for mRNA-based therapeutics," Hum. Vaccines Immunother., vol. 22, no. 1, p. 2635868, 2026.
L. L. Kenney et al., "mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity," Cell Rep. Med., vol. 5, no. 9, 2024.
M. C. Gissler, F. S. Picard, T. Marchini, H. Winkels, and D. Wolf, "mRNA Vaccination for Induction of Immune Tolerance Against Autoimmune Disease," Trends mRNA Vaccine Res., pp. 201-240, 2025.
R. Deyhimfar et al., "The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases," Heliyon, vol. 10, no. 5, 2024.
N. Chahin et al., "Twelve-month follow-up of patients with generalized myasthenia gravis receiving BCMA-directed mRNA cell therapy," medRxiv, Jan. 2024.
O. B. Obi, "mRNA Therapeutics Beyond Vaccines: A Platform Technology for Cancer, Autoimmune, and Genetic Disorders," Autoimmune Genet. Disord., Jan. 2026.
O. P. C. Ugwu, F. C. Ogenyi, M. Basajja, C. N. Ugwu, M. M. Mustafa, and M. B. Okon, "Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review," Front. Drug Deliv., vol. 6, p. 1793322, 2026.
M. D. Miljkovic et al., "Safety and tolerability of BCMA-directed mRNA CAR T-cell therapy in multiple myeloma and autoimmune disease," Blood, vol. 144, p. 2080, 2024.
A. S. Thatte et al., "mRNA lipid nanoparticles for ex vivo engineering of immunosuppressive T cells for autoimmunity therapies," Nano Lett., vol. 23, no. 22, pp. 10179-10188, 2023.
A. R. Lee et al., "A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects," Front. Immunol., vol. 16, p. 1665998, 2025.
R. Razavi, M. Kegel, J. Muscat-Rivera, D. Weissman, and J. R. Melamed, "Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases," Mol. Ther. Methods Clin. Dev., vol. 33, no. 3, 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Emily Davis (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
